Evidence map›Paper›PMID 41031895›Full record

ReviewThe Journal of clinical investigation2025

Emerging roles for complement in lung transplantation.

Hrishikesh S Kulkarni, John A Belperio, Carl Atkinson

Abstract readReview
In one paragraph

Review in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hrishikesh S KulkarniDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USA.
John A BelperioDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USA.
Carl AtkinsonDepartment of Surgery, Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Funding

Lung Transplant Clinical Trial Network (LT-CTN)U01AI163099 · NIAID · DUKE UNIVERSITY · PI JOHN A BELPERIO, Scott M Palmer · 2021 to 2026
$17.8M
Lung epithelial cell-derived C3 in acute lung injuryR01HL169860 · NHLBI · WASHINGTON UNIVERSITY · PI Hrishikesh Satish Kulkarni · 2023 to 2026
$2.3M
Lung-derived complement in pneumoniaR01HL166449 · NHLBI · WASHINGTON UNIVERSITY · PI Hrishikesh Satish Kulkarni · 2023 to 2026
$2.2M
Targeted delivery of immunosuppressive agents to the graft endothelium forthe prevention of rejection in lung transplantationU01AI170075 · NIAID · UNIVERSITY OF FLORIDA · PI Carl Atkinson, JASON R. McCARTHY · 2022 to 2026
$2.1M
Complement driven innate and adaptive autoreactivity in lung transplantationR01HL140470 · NHLBI · UNIVERSITY OF FLORIDA · PI ATKINSON, CARL · 2018 to 2021
$2.0M
NHLBI NIH HHS R01 HL140470NHLBI NIH HHS R01 HL166449NHLBI NIH HHS R01 HL169860NIAID NIH HHS U01 AI163099NIAID NIH HHS U01 AI170075
6 · The paper itself

Abstract

The complement system is an evolutionarily conserved host defense system that has evolved from invertebrates to mammals. Over time, this system has become increasingly appreciated as having effects beyond purely bacterial clearance, with clinically relevant implications in transplantation, particularly lung transplantation. For many years, complement activation in lung transplantation was largely focused on antibody-mediated injuries. However, recent studies have highlighted the importance of both canonical and noncanonical complement activation in shaping adaptive immune responses, which influence alloimmunity. These studies, together with the emergence of FDA-approved complement therapeutics and other drugs in the pipeline that function at different points of the cascade, have led to an increased interest in regulating the complement system to improve donor organ availability as well as improving both short- and long-term outcomes after lung transplantation. In this Review, we provide an overview of the when, what, and how of complement in lung transplantation, posing the questions of: when does complement activation occur, what components of the complement system are activated, and how can this activation be controlled? We conclude that complement activation occurs at multiple stages of the transplant process and that randomized controlled trials will be necessary to realize the therapeutic potential of neutralizing this activation to improve outcomes after lung transplantation.

Indexed as

Complement ActivationComplement System ProteinsLung TransplantationAdaptive ImmunityAnimalsGraft RejectionHumansComplement System Proteins

Identifiers

PMID41031895
PMCPMC12483610

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.